<DOC>
	<DOCNO>NCT00035854</DOCNO>
	<brief_summary>This study treat pediatric patient infection due specific bacteria ( Vancomycin-Resistant Enterococcus )</brief_summary>
	<brief_title>New Antibiotic Treat Pediatric Patients With Infections Due Specific Bacteria ( Vancomycin-Resistant Enterococcus )</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Linezolid</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<criteria>Other specific inclusion/exclusion criterion may apply . In order determine eligibility , examination investigator necessary . Hospitalized/chronic care pediatric patient ( birth 17 year ) Known infection due vancomycinresistant enterococcus specie , include diagnosis hospitalacquired pneumonia , complicate skin skin structure infection , catheterrelated bacteremia , bacteremia unidentified source , infection Requires minimum 3 day IV medication Patients mixed infection due VRE &amp; gram negative bacteria allow enroll study . For infection , 2 additional symptom require . Potentially effective concomitant antibiotic A high surgical cure rate Medical condition would preclude clinical evaluation require treatment long duration 28 day 24 hour antibiotic treatment within 48 hour study entry ( unless preapproved ) Having infect device could remove</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Pharmacia</keyword>
	<keyword>Drug Resistance , Microbial</keyword>
</DOC>